Section: 
School of pharmacotherapy
School of pharmacotherapyUnresolved issues of management of patients with severe allergic rhinitis and nasal polyposis. The possibilities of anti-IgE therapy
Chernykh A. V. (1), Mashkova T. A. (1), Mal’tsev A. B. (1)
(1) Burdenko Voronezh State Medical Academy, Voronezh, 394036, Russia
UDK: 16.211-002.193-056.3+616.216.1-002-006.5-032.81-07
DOI: https://doi.org/10.18692/1810-4800-2020-3-88-99
ABSTRACT
The current state of the patients’ management with nasal polyposis and allergic rhinitis has become the basis for a deep analysis of the currently available data on the prevalence of diseases (with a focus on severe forms), as well, available possibilities and disadvantages of conservative therapy are considered. The approaches to assessing the severity and control of diseases and the influence of an uncontrolled course on the quality of the patients’ life are presented. Particular attention is paid to a new class of drugs – monoclonal antibodies, which might change the patients’ treatment paradigm of severe uncontrolled course of allergic rhinitis and nasal polyposis. The efficacy and safety issues of immunobiological therapy are discussed on the example of the IgE-targeted medicine omalizumab. The potential place of the drug in the treatment of the mentioned above forms of nasal polyposis and allergic rhinitis is indicated.
Publication date:
25.06.2020
Keywords:
nasal polуposis, allergic rhinitis, severe uncontrolled course, standard therapy, monoclonal antibodies, omalizumab.
For citation:
Emel’yanov A. V., Il’ina N. I., Karneeva O. V., Karpishchenko S. A., Kim I. A., Kurbacheva O. M., Nenasheva N. M., Obukhova O. V., Svistushkin V. M., Ukhanova O. P. Unresolved issues of management of patients with severe allergic rhinitis and nasal polyposis. The possibilities of anti-IgE therapy. Rossiiskaya otorinolaringologiya. 2020;19(3):88–99. https://doi.org/10.18692/1810-4800-2020-3-88-99